An Exploratory Study on the Safety and Effectiveness of Autoimmune Cell Therapy Sensitized With Liver Cancer Neoantigen in Patients With High Risk of Recurrence After Surgical Resection of Primary Hepatocellular Carcinoma
Latest Information Update: 12 Nov 2021
Price :
$35 *
At a glance
- Drugs IPM 001 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 12 Nov 2021 New trial record